A quiet FDA rule change — letting bone-density scans stand in for fractures in trials — is reigniting drugmaker and investor interest in a common disease that had fallen out of fashion.
In a rare joint letter, the chairs of Europe’s biggest drugmakers say the continent’s share of pharmaceutical research and investment is sliding — and urge governments to act before the decline becomes permanent.
The deal for a preclinical radioligand therapy deepens Novartis’s lead in targeted radioactive cancer treatment — and adds to a rush of Western pharma licensing innovative assets from China.
Envisagenics uses machine learning to mine “RNA splicing” — a largely untapped source of cancer targets — and Boehringer Ingelheim is paying up to $1 billion to turn those targets into precision therapies.
Basecamp Research trained a biological “foundation model” on the world’s largest proprietary gene dataset — and wants to use it to design therapies that reprogram a patient’s own cells inside the body.
Veterans who came off GLP-1 medications faced a rising risk of heart attack, stroke and death — up 22% after two years — suggesting the drugs’ cardiovascular protection fades fast once you stop.
PET imaging found long-COVID patients have fewer healthy dopamine-releasing neurons in key brain regions — a possible biological explanation for the fatigue, sluggishness and memory problems, and a target for treatment.
Celldex’s barzolvolimab cleared chronic hives in about half of patients — data one analyst called the best they’d seen — but two anaphylaxis cases sent the shares down and clouded an otherwise strong readout.
Dazodalibep met its main targets in a Phase 3 trial for Sjögren’s — the autoimmune disease that dries out eyes and mouths for up to 4 million Americans and has never had an FDA-approved therapy.
A new report finds the American cancer death rate has dropped by more than a third over three decades — the result of less smoking, earlier detection and better treatment — even as new challenges loom.
A viral protein called ORF8 tricks immune cells into becoming gateways for infection, driving the runaway lung inflammation of severe COVID — and pointing to an existing drug that might interrupt it.
Lilly’s Inluriyo plus Verzenio is now cleared for ER-positive, HER2-negative breast cancer with an ESR1 mutation — a resistance driver — after a trial showed switching to the combo doubled how long the cancer stayed in check.